Sheikh Mohammad Abdurrehman, Moon Michelle P, Wright Clinton B, Gutierrez Jose, Liu Minghua, Rundek Tatjana, Cheung Ken, Hornig Mady, Elkind Mitchell S V
Department of Neurology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA.
Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Brain Behav Immun Health. 2024 Dec 24;43:100937. doi: 10.1016/j.bbih.2024.100937. eCollection 2025 Feb.
To determine whether a panel of immune markers adds significant information to known correlates of risk of dementia and cognitive impairment.
The impact of immune mechanisms on dementia risk is incompletely characterized.
DESIGN/METHODS: A subsample of the Northern Manhattan Study, a prospective cohort study in the racially/ethnically diverse population of New York City, underwent comprehensive neuropsychological testing up to three times, at approximately 5-year intervals. Cognitive outcomes were adjudicated as no cognitive impairment, mild cognitive impairment (MCI), or dementia. Immune markers were assessed using a multiplex immunoassay on plasma samples collected at the time of the first neuropsychological test. Least absolute shrinkage and selection operator (LASSO) techniques were employed to yield a panel of immune markers linearly related to the outcome of dementia/MCI vs. no cognitive impairment. Nested logistic regression models were run to determine the independent association of the immune marker panel with dementia/MCI after adjusting for other predictors of risk.
Among 1179 participants (mean age 70.0 ± 8.9 years, 60% women, 68% Hispanic), immune markers improved model fit above demographic and vascular risk factors (p-value for likelihood ratio test <0.0001) as correlates of MCI/dementia. Individual immune markers found to be associated with dementia/MCI were C-X-C Motif Chemokine Ligand 9 (CXCL9) and C-C Motif Chemokine Ligand 2 (CCL2). The effect of the immune markers was comparable to traditional risk factors, with CCL2 (per SD) having almost the same effect as 1 year of aging and CXCL9 (per SD) showing approximately twice this magnitude.
Immune markers are associated with cognitive decline and dementia outcomes in a multi-ethnic cohort. More work is needed to further characterize these associations and determine therapeutic strategies. (Funded by the National Institute of Health/National Institute of Neurological Disorders and Stroke; grant number R01 29993 (Sacco/Elkind)).
确定一组免疫标志物是否能为已知的痴呆和认知障碍风险相关因素增添重要信息。
免疫机制对痴呆风险的影响尚未完全明确。
设计/方法:北曼哈顿研究的一个子样本进行了全面的神经心理学测试,该研究是一项针对纽约市种族/民族多样化人群的前瞻性队列研究,测试间隔约为5年,最多进行三次。认知结果被判定为无认知障碍、轻度认知障碍(MCI)或痴呆。在首次神经心理学测试时采集的血浆样本上,使用多重免疫测定法评估免疫标志物。采用最小绝对收缩和选择算子(LASSO)技术得出一组与痴呆/MCI结局和无认知障碍线性相关的免疫标志物。在调整其他风险预测因素后,运行嵌套逻辑回归模型以确定免疫标志物组与痴呆/MCI的独立关联。
在1179名参与者中(平均年龄70.0±8.9岁,60%为女性,68%为西班牙裔),作为MCI/痴呆的相关因素,免疫标志物在人口统计学和血管危险因素之上改善了模型拟合度(似然比检验的p值<0.0001)。发现与痴呆/MCI相关的个体免疫标志物为C-X-C基序趋化因子配体9(CXCL9)和C-C基序趋化因子配体2(CCL2)。免疫标志物的作用与传统风险因素相当,CCL2(每标准差)的作用几乎与1年衰老相同,CXCL9(每标准差)的作用约为此的两倍。
免疫标志物与多民族队列中的认知衰退和痴呆结局相关。需要更多工作来进一步描述这些关联并确定治疗策略。(由美国国立卫生研究院/国立神经疾病和中风研究所资助;拨款编号R01 29993(萨科/埃尔金德))